Harpoon Therapeutics has selected CMC Biologics to develop and manufacture three molecules for cancer treatments at the CDMO’s facilities in California and Washington State, US.
Teva Pharmaceuticals Australia has selected Berkeley Lights’ biological workflow platform to develop therapeutic antibodies at its R&D site in New South Wales.
The world’s largest single bioproduction plant has received its first EU regulatory approval to make a monoclonal antibody, says CDMO Samsung Biologics.
Abzena has negotiated the lease on a 50,000 square foot site in San Diego as part of a $17m remodelling of its bioproduction and conjugation facilities.
CSL opens a $173m albumin plant in Australia, Kiadis leases a facility in The Netherlands, and ADC Bio signs a construction agreement in Wales. Welcome to Biopharma-Reporter’s facility round-up.
Vendors say they are open to considering a singular, industry-wide design for disposable bioreactor equipment, IP concerns and customised demands could impede its adoption.
The Korean CDMO says construction of its third – and largest – biomanufacturing facility is complete with the validation process expected to take a year.
Single-use demand grew so fast vendors were unable to keep up, says MilliporeSigma which has since tackled this through investments and a standardised offering.
By InVitria launches xeno-free service within $5.2bn media market
Xeno-free media will continue to increase its share of the estimated 30m litre mammalian cell culture market says InVitria, which has launched a new formulation service.
Standardising disposable bioreactor technology – starting with the buffer bag – will help ensure single-use supply chain security, says biomanufacturing consultant David Wolton.
Following a ¥14bn ($125m) investment in April, Fujifilm Corporation has committed a further ¥3.2bn across its biologics contract manufacturing business.
Pall Corporation will equip WuXi Biologics’ continuous bioprocess laboratory in Shanghai, China, which the latter said would expand process scale and reduce manufacturing costs.
Nearly half the respondents of our second state of the global biomanufacturing survey believe we are too reliant on Chinese Hamster Ovary (CHO) expression systems.
Size can be a restricting factor when introducing single-use technologies into a pre-existing facility according to BMS, which hopes to integrate disposable equipment at a US-based site.
Sartorius Stedim Biotech (SSB) has cut its full year guidance, citing the negative impact of hurricane Maria, customer destocking and ongoing issues with a cell culture media supplier.
Fresh from US approval of its second facility and ahead of the opening of a third, Samsung Biologics is now considering a fourth plant outside of Korea.
The Modular Automated Sampling Technology (MAST) platform, which allows direct transfer of aseptically collected bioreactor samples to analytical devices, won the CPhI Worldwide award for bioprocessing last night.
By Cutting the cost of vaccine manufacture, Univercells
High-density single-use bioreactors, small facilities and continuous manufacturing will cut the cost of manufacturing polio vaccines down to $0.15 per dose, says Univercells.
Faster and more flexible biomanufacturing models are necessary to reduce the cost of biologics, says Just Biotherapeutics which is building a deployable modular facility in China.
The contract development and manufacturing organisation (CDMO) has selected Pall Life Sciences as its single-use equipment partner at its sites in Florida and Massachusetts.
Lonza has launched an updated version of its cell imaging technology, which it says has improved image capture and data transfer options, and enables researchers to monitor cells remotely.
SGI-DNA has selected BioCat to distribute its protein expression platform Vmax Express, which it says is more rapid than traditional expression systems.
Gilead says it is committed to driving down costs of CAR-T manufacturing after agreeing to buy late-stage cell and gene therapy firm KitePharma for $11.9bn.
Oxford BioMedica saw its share price jump 21% after the US FDA approved Kymriah, the gene modified cell therapy made with the firm’s lentiviral vectors.
